Open Collections

UBC Faculty Research and Publications

New drugs VII Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 44 reviews four newer drugs: mirtazapine, salmon-calcitonin nasal spray, gatifloxacin, and moxifloxacin. Mirtazapine has no proven efficacy or safety advantage over other antidepressant therapies. It has a prominent sedative effect and patients should be warned that it may cause mental or motor impairment. Salmon-calcitonin nasal spray reduces radiographically-detected new vertebral collapse in patients with at least one vertebral collapse and low BMD (ARR 8.3%), but has no effect on non-vertebral fractures. Long term compliance is poor, even in a trial setting. Gatifloxacin and moxifloxacin have no proven clinical advantages over other fluroquinolones, macrolides or amoxicillin. Based on cost they are not first choice drugs for their approved indications.

Item Metadata

Title
New drugs VII
Alternate Title
Therapeutics Letter 44
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2002-05
Description
Therapeutics Letter 44 reviews four newer drugs: mirtazapine, salmon-calcitonin nasal spray, gatifloxacin, and moxifloxacin. Mirtazapine has no proven efficacy or safety advantage over other antidepressant therapies. It has a prominent sedative effect and patients should be warned that it may cause mental or motor impairment. Salmon-calcitonin nasal spray reduces radiographically-detected new vertebral collapse in patients with at least one vertebral collapse and low BMD (ARR 8.3%), but has no effect on non-vertebral fractures. Long term compliance is poor, even in a trial setting. Gatifloxacin and moxifloxacin have no proven clinical advantages over other fluroquinolones, macrolides or amoxicillin. Based on cost they are not first choice drugs for their approved indications.
Subject
Antidepressive Agents; Anti-Bacterial Agents; Calcitoniin; Gatifloxacin; Hypnotics and Sedatives; Mirtazapine; Moxifloxacin
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433623
URI
http://hdl.handle.net/2429/85033
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International